Methylation markers for diagnosis and treatment of ovarian cancer
US7507536B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 6, 2006 |
| Grant date | Mar 24, 2009 |
| Priority date | — |
| Expiry date | Oct 6, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/154
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Twenty-three markers are provided which are epigenetically silenced in ovarian cancers. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.